• Decrease font size
  • Return font size to normal
  • Increase font size
U.S. Department of Health and Human Services

Search Orphan Drug Designations and Approvals

  • Print
  • Share
  • E-mail
-
Generic Name: selective inhibitor of dual-specific protein kinase mitogen-activated protein kinase kinase 4 (MKK4)
Date Designated: 08/10/2026
Orphan Designation: prevention of post-hepatectomy liver failure
Orphan Designation Status: Designated
FDA Orphan Approval Status: Not FDA Approved for Orphan Indication
HepaRegeniX GmbH
Eisenbahnstrasse 63
Tubingen, NA 72072
Germany

The sponsor address listed is the last reported by the sponsor to OOPD.

*Exclusivity Protected Indications are shown for approvals from 01/01/2013 to the present.
*Data for the Date Designation Withdrawn or Revoked field are shown for designations withdrawn or revoked after 08/12/2013.
-
-